TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock
15 août 2023 06h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock
14 août 2023 16h01 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023
09 août 2023 08h30 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections
31 juil. 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
Voriconazole Inhalation Powder (TFF VORI) is an investigational, inhaled formulation of voriconazole developed using TFF Pharmaceuticals Thin Film Freezing technology that is currently being evaluated...
TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine
26 juin 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered...
TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
23 mai 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences...
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases
04 mai 2023 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program
01 mai 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
07 mars 2023 16h15 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...